SCHEMBL1649243

SCHEMBL1649243

O=C(O)c1ccc(OCc2ccccc2)c(C(=O)O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.68
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 1/20 0.62
POLB P06746 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
NR4A2 P43354 2/20 0.58
NR4A1 P22736 1/20 0.58
NR4A3 Q92570 1/20 0.58
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
PTGER1 P34995 1/20 0.57
RXRA P19793 3/20 0.55
RXRB P28702 2/20 0.55
HPGD P15428 2/20 0.55
RXRG P48443 1/20 0.55
MRGPRX4 Q96LA9 4/20 0.55
NPC1 O15118 1/20 0.55
MITF O75030 1/20 0.55
TP53 P04637 1/20 0.55
XBP1 P17861 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131229 0.89 FOLH1 (0.63) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL7934406 0.89 FOLH1 (0.69) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL1316640 0.88 ALDH1A1 (0.56) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL4295650 0.88 FOLH1 (0.62) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL2634130 0.87 NR4A2 (0.63) FOLH1NR4A2NR4A1NR4A3MEN1
SCHEMBL11536692 0.87 KDM4E (0.62) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL551475 0.87 FOLH1 (0.60) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL383508 0.87 FOLH1 (0.60) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL5485828 0.87 SMPD1 (0.70) FOLH1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL5485830 0.87 SMPD1 (0.62) FOLH1NR4A2NR4A1NR4A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483254-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-08-13 EP disclosed
US-8778939-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-07-15 US disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed
CN-100519546-C Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics UNIVERSTE LOUIS PASTEUR CT NAT (FR) 2009-07-29 CN disclosed
CN-1849312-A Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics UNIV PASTEUR (FR) 2006-10-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184553-A1 NOVEL COMPOUNDS LRRK2, PARK7, PINK1 FOLH1 4250/4885KDM4E 3000/4885ALDH1A1 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.